Answers are grounded in this paper and cite their sources.
Reports pharmacokinetic similarities of tegoprazan in Mexicans and Koreans, suggesting broader applicability of findings.
Since no clinically relevant pharmacokinetic differences were observed in the pharmacokinetics of tegoprazan, a substrate for CYP3A4, between Mexicans and Koreans, it is concluded that the efficacy and safety data for tegoprazan obtained in Koreans will be valid in the Mexican population.
No takes yet. Share an insight, caveat, or question.
Carrasco-Portugal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: